Advertisement

Clinical Pharmacokinetics

, Volume 34, Issue 1, pp 79–90 | Cite as

Optimisation of Cyclophosphamide Therapy in Systemic Vasculitis

  • Ruth Richmond
  • Tracy W. McMillan
  • Raashid A. Luqmani
Review Article Disease Management

Summary

There is no doubt that the prognosis for systemic vasculitides has been considerably improved by the use of immunosuppressive agents, chiefly cyclophosphamide. Increasingly, we are becoming aware of the enormous burden of chronic ‘grumbling’ disease, the high incidence of relapse and the longer term effects of toxic therapy in these patients. The general approach is more intense therapy (with intermittent high dose ‘pulses’ or lower dose continuous cyclophosphamide) in the initial phase of therapy to induce remission, followed by a less toxic therapy in the maintenance phase (either longer intervals between pulses or a switch to a less toxic drug, such as azathioprine).

The pathogenetic mechanisms in vasculitis, which are becoming more precisely defined, are diverse, but cyclophosphamide remains the drug of choice. A number of different cyclophosphamide regimens are in use, which reflects the current dilemma of trying to balance effectiveness with toxicity in diseases where the quality of long term survival remains unsatisfactory.

Evidence from controlled trials does not support major differences in immediate outcome between different regimens of cyclophosphamide. Future studies need to address the use of agents designed to interfere precisely with the underlying pathogenetic mechanisms. Alternative approaches should also be considered, for example the use of sublethal doses of cyclophosphamide, with autologous bone marrow rescue, which may achieve long lasting remission or even cure.

Keywords

Cyclophosphamide Vasculitis Adis International Limited Lupus Nephritis Herpes Zoster 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kussmaul A, Maier R. Ueber eine bisher nicht beschriebene eigenthmliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellahmung einhergeht. German Arch Clin Med 1866; 1: 484–518.Google Scholar
  2. 2.
    Mattheson EL. On a previously undescribed peculiar arterial disease (Periarteritis nodosa) accompanied by Blight’s disease and rapidly progressive muscle weakness (original translation from Kussmaul and Maier). Rochester: Mayo Press, 1996.Google Scholar
  3. 3.
    Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187–92.PubMedGoogle Scholar
  4. 4.
    Scott DGI, Watts RA. Classification and epidemiology of systemic vasculitis. Br J Rheumatol 1994; 33: 897–900.PubMedGoogle Scholar
  5. 5.
    Mason PD, Pusey CD. Glomerulonephritis: diagnosis and treatment. BMJ 1994; 309: 1557–63.PubMedGoogle Scholar
  6. 6.
    Walton EW. Giant-cell granuloma of the respiratory tract. BMJ 1958; 2: 265–70.PubMedGoogle Scholar
  7. 7.
    Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener’s granulomatosis. Ann Intern Med 1967; 67: 393–8.PubMedGoogle Scholar
  8. 8.
    Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43: 8–14.PubMedGoogle Scholar
  9. 9.
    Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine 1973; 52: 535–61.PubMedGoogle Scholar
  10. 10.
    Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe necrotizing vasculitis. N Engl J Med 1979; 301: 235–8.PubMedGoogle Scholar
  11. 11.
    Leib ES, Restivo C, Paulus HC. Immunosuppressive and corticosteroid therapy of periarteritis nodosa. Am J Med 1979; 67: 941–7.PubMedGoogle Scholar
  12. 12.
    Fauci AS, Barton H, Katz P, et al. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85.PubMedGoogle Scholar
  13. 13.
    Hoffman GS, Kerr GS, Leavitt R, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488–98.PubMedGoogle Scholar
  14. 14.
    Matteson EL, Gold KN, Bloch DA, et al. Long term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s granulomatosis classification criteria cohort. Am J Med 1996; 101: 129–34.PubMedGoogle Scholar
  15. 15.
    Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779–90.PubMedGoogle Scholar
  16. 16.
    Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener’s granulomatosis. Ann Intern Med 1996; 124: 477–84.PubMedGoogle Scholar
  17. 17.
    Exley AR, Moots RJ, Carruthers D, et al. Short form 36 in vasculitis. Clin Exp Immunol 1995; 101 Suppl. 1: 63.Google Scholar
  18. 18.
    Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the vasculitis damage index (VDI) for the standardised clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371–80.PubMedGoogle Scholar
  19. 19.
    Arnold H, Bourseaux F. Synthese und Abbau cytostatisch wirksamer cyclischer N-Phosphamidester des Bis (beta chlorathyl) amins. Angewandte Chemie 1958; 70: 539–44.Google Scholar
  20. 20.
    Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharamcokinet 1991; 20: 194–208.Google Scholar
  21. 21.
    Scott DGI, Bacon PA, Allen C, et al. IgG rheumatoid factor complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol 1981; 43: 54–63.PubMedGoogle Scholar
  22. 22.
    Cochrane CG, Aiken BS. Polymorpholeukocytes in immunologic reactions: the destruction of vascular basement membranes in vivo and in vitro. J Exp Med 1966; 124: 733–52.PubMedGoogle Scholar
  23. 23.
    Cochrane CG. Immunologic tissue injury mediated by neutrophilic leukocytes. Adv Immunol 1968; 9: 97–162.PubMedGoogle Scholar
  24. 24.
    Bast RC Jr, Reinherz EL, Maver C, et al. Contrasting effects of cyclophosphamide and prednisone on the phenotype of human peripheral blood lymphocytes. Clin Immunol Immunopathol 1983; 28: 101–14.PubMedGoogle Scholar
  25. 25.
    Hemendinger RA, Bloom SE. Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacol 1996; 35: 71–82.Google Scholar
  26. 26.
    Mountz JD, Wu J, Cheng J, et al. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415–20.PubMedGoogle Scholar
  27. 27.
    Miller TE, North DK. Clinical infections, antibiotics and immunosuppression: a puzzling relationship. Am J Med 1981; 71: 334–6.PubMedGoogle Scholar
  28. 28.
    Shimizu A, Kitamura H, Masuda Y, et al. Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int 1995; 47: 114–21.PubMedGoogle Scholar
  29. 29.
    Meyn RE, Stephens C, Hunter NR, et al. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994; 33: 410–4.PubMedGoogle Scholar
  30. 30.
    Chen B, Cyr DG, Hales BF. Role of apoptosis in mediating phosphoramide mustard-induced rat embryo malformations in vitro. Teratology 1994; 50: 1–12.PubMedGoogle Scholar
  31. 31.
    Moallem SA, Hales BF. Induction of apoptosis and cathepsin D in limbs exposed in vitro to an activated analog of cyclophosphamide. Teratology 1995; 52: 3–14.PubMedGoogle Scholar
  32. 32.
    Colucci F, Cilio CM, Lejon K, et al. Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. J Autoimmun 1996; 9: 271–6.PubMedGoogle Scholar
  33. 33.
    Rasmussen N, Jayne DRW, Abramowicz D, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101: 29–34.Google Scholar
  34. 34.
    Bagley CM, Bostick FW, DeVita VD. Clinical pharmacology of cyclophosphamide. Cancer Res 1973; 33: 226–35.PubMedGoogle Scholar
  35. 35.
    Struck RF, Alberts DS, Home K, et al. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomised crossover trial. Cancer Res 1987; 47: 2723–6.PubMedGoogle Scholar
  36. 36.
    Belfayol L, Guillevin L, Louchahi K, et al. Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis. Fundamen Clin Pharmacol 1994; 8: 458–62.Google Scholar
  37. 37.
    Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1979; 4: 380–94.PubMedGoogle Scholar
  38. 38.
    Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984; 26: 591–3.PubMedGoogle Scholar
  39. 39.
    Austin HA, Klippel JH, Balow, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614–9.PubMedGoogle Scholar
  40. 40.
    Carruthers DM, Watts RA, Scott DGI. Pulse cyclophosphamide therapy in systemic vasculitis [abstract]. Br J Rheumatol 1995; 34 Suppl. 1: 21.Google Scholar
  41. 41.
    D’Cruz D, Froes LD, Lloyd ME, et al. Low-dose intravenous cyclophosphamide in systemic vasculitis. Arthritis Rheum 1996 Sep; 39 Suppl.: S219.Google Scholar
  42. 42.
    Froes L, D’Cruz D, Lloyd ME, et al. Intravenous cyclophosphamide in the treatment of systemic vasculitis: a five year follow-up study [abstract]. Br J Rheumatol 1995; 34 Suppl. 1: 22.Google Scholar
  43. 43.
    Guillevin L, Leclerq B, Jarrousse P, et al. Treatment of severe Wegener’s granulomatosis: a prospective trial in 27 patients comparing prednisolone, pulse cyclophosphamide versus prednisolone and oral cyclophosphamide: a preliminary report [abstract]. Arthritis Rheum 1993; 36 Suppl.: S140.Google Scholar
  44. 44.
    Hoffman GS, Leavitt RY, Fleisher TA, et al. Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403–10.PubMedGoogle Scholar
  45. 45.
    Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76: 377–84.PubMedGoogle Scholar
  46. 46.
    Boumpas DT, Austin JH, Vaughan EM, et al. Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366–9.PubMedGoogle Scholar
  47. 47.
    Stillwell TJ, Benson RC, DeRemee RA, et al. Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum 1988; 31: 465–70.PubMedGoogle Scholar
  48. 48.
    Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45–53.PubMedGoogle Scholar
  49. 49.
    DeVries CR, Freiha FS. Haemorrhagic cystitis: a review. J Urol 1990; 143: 1–7.Google Scholar
  50. 50.
    Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic disease. Semin Arthritis Rheum 1983; 12: 359–72.PubMedGoogle Scholar
  51. 51.
    Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 1971; 284: 938–42.PubMedGoogle Scholar
  52. 52.
    Hoffman GS. Vasculitic syndromes. Curr Opin Rheumatol 1994; 6: 1–2.Google Scholar
  53. 53.
    Gross WL. New developments in the treatment of systemic vasculitis. Current Opin Rheumatol 1994; 6: 11–9.Google Scholar
  54. 54.
    Bacon PA. Therapy of vasculitis. J Rheumatol 1994; 21: 788–90.PubMedGoogle Scholar
  55. 55.
    Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997; 90: 401–9.Google Scholar
  56. 56.
    Chapman PT, O’Donnel JL. Respiratory failure in Wegener’s granulomatosis: response to pulse intravenous methylprednisolone and cyclophosphamide. J Rheumatol 1993; 20: 504–6.PubMedGoogle Scholar
  57. 57.
    Fort JG, Abruzzo JL. Reversal of necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis Rheum 1988; 31: 1194–8.PubMedGoogle Scholar
  58. 58.
    Guillevin L, Lhote F, Cohen P, et al. Corticosteroid plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome in patients with factors predicting poor prognosis: a prospective, randomised trial in sixty-two patients. Arthritis Rheum 1995; 11: 1638–45.Google Scholar
  59. 59.
    Haga HJ, D’Cruz D, Asherson R, et al. Short term effects of intravenous pulses of cyclophosphamide in treatment of connective tissue disease crisis. Ann Rheum Dis 1992; 51: 885–8.PubMedGoogle Scholar
  60. 60.
    Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener’s granulomatosis. Arthritis Rheum 1994; 37: 919–24.PubMedGoogle Scholar
  61. 61.
    Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945–50.PubMedGoogle Scholar
  62. 62.
    Gayraud M, Leclerq P, Guillevin L. Treatment of good prognosis-polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS): comparison of steroids and two cyclophosphamide (CY) regiments (daily oral or monthly pulses) in 25 patients. Arthritis Rheum 1994; 37 Suppl.: 352.Google Scholar
  63. 63.
    De Vita S, Neri R, Bombardieri S. Cyclophosphamide pulses in the treatment of rheumatic diseases: an update. Clin Exp Rheumatol 1991; 9: 179–93.PubMedGoogle Scholar
  64. 64.
    Drosos AA, Sakkas LI, Goussia A, et al. Pulse cyclophosphamide therapy in Wegener’s granulomatosis: a pilot study. J Intern Med 1992; 232: 279–82.PubMedGoogle Scholar
  65. 65.
    Haubitz M, Frei U, Rother U, et al. Cyclophosphamide pulse therapy in Wegener’s granulomatosis. Nephrol Dial Transplant 1991; 6: 531–5.PubMedGoogle Scholar
  66. 66.
    Le Thi Huong D, Papo T, Piette JC, et al. Monthly intravenous pulse cyclophosphamide therapy in Wegener’s granulomatosis. Clin Exp Rheumatol 1996; 14: 9–16.PubMedGoogle Scholar
  67. 67.
    Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1996; 34: 737–41.Google Scholar
  68. 68.
    McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224–9.PubMedGoogle Scholar
  69. 69.
    Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination in patients with lupus nephritis: a randomised, controlled trial. Ann Intern Med 1996; 125: 549–57.PubMedGoogle Scholar
  70. 70.
    Gibbon RB, Westerman E. Acute non-lymphocytic leukaemia following short-term intermittent intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 1988; 31: 1552–4.Google Scholar
  71. 71.
    Guillevin L, Jarrousse B, Lok C, et al. Long-term follow-up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison to steroids, plasma exchange and cyclophosphamide to steroid and plasma exchange: a prospective randomised trial of 71 patients. J Rheumatol 1991; 18: 567–74.PubMedGoogle Scholar
  72. 72.
    Guillevin L, Le Thi Huong D, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988; 27: 258–66.PubMedGoogle Scholar
  73. 73.
    Jayne DRW, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737–47.PubMedGoogle Scholar
  74. 74.
    Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121: 484–91.PubMedGoogle Scholar
  75. 75.
    Weyand CM, Schonberger J, Oppitz V, et al. Distinct vascular lesions in giant cell arteritis share identical T-cell clonotypes. J Exp Med 1994; 179: 951–60.PubMedGoogle Scholar
  76. 76.
    Hagen EC, De Keizer RJW, Andrassy K, et al. Compassionate treatment of Wegener’s granulomatosis with rabbit antithymocyte globulin. Clin Nephrol 1995; 43: 351–9.PubMedGoogle Scholar
  77. 77.
    Lockwood CM, Thiru S, Isaacs JD, et al. Humanised monoclonal antibody therapy for intractable systemic vasculitis. Lancet 1993; 341: 1620–2.PubMedGoogle Scholar
  78. 78.
    Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodies. Q J Med 1996; 89: 903–12.Google Scholar
  79. 79.
    Savage COS. The interaction of endothelial cells with inflammatory cells in vasculitis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 1996; 13: 214–6.Google Scholar
  80. 80.
    Bradley JR, Lockwood CM, Thiru S. Endothelial cell activation in patients with systemic vasculitis. Q J Med 1994; 87: 741–5.Google Scholar
  81. 81.
    Drummond C, Lockwood CM, Merrill C, et al. Intervention in clinical refractory systemic vasculitis by humanised monoclonal antibodies against adhesion molecules [abstract]. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 1996; 13: 277.Google Scholar
  82. 82.
    Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996; 104 Suppl. 1: 77–82.PubMedGoogle Scholar
  83. 83.
    Richter C, Schnabel A, Csernok E, et al. Treatment of Wegener’s granulomatosis with intravenous immunoglobulin. In: Gross WL, editor. ANCA-associated vasculitides. London: Plenum Press, 1993.Google Scholar
  84. 84.
    Jayne DRW, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993; 336: 469–72.PubMedGoogle Scholar
  85. 85.
    Jayne DRW, Lockwod CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35: 1150–3.PubMedGoogle Scholar
  86. 86.
    Chapman PT, Griffin SV, Moguilevsky N, et al. The use of a recombinant myeloperoxidase (rec-MPO) column to selectively remove anti-MPO antibodies from human sera: preclinical feasibility studies [abstract]. Sarcoidosis, Vasculitis and Diffuse Lung Disease 1996; 13 Suppl.: 276.Google Scholar
  87. 87.
    Goldman JA, Casey HL, McIlwain H, et al. Limited plasmapheresis in rheumatoid arthritis with vasculitis. Arthritis Rheum 1979; 22: 1146–50.PubMedGoogle Scholar
  88. 88.
    Scott DGI, Bacon PA, Bothamley JE, et al. Plasma exchange in rheumatoid vasculitis. J Rheumatol 1981; 8: 433–9.PubMedGoogle Scholar
  89. 89.
    Guillevin L, Lhote F, Leon A, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges: a prospective trial in 33 patients. J Rheumatol 1993; 20: 289–98.PubMedGoogle Scholar
  90. 90.
    Guillevin L, Lhote F, Sauvaget, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53: 334–7.PubMedGoogle Scholar
  91. 91.
    Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a randomised controlled trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638–45.PubMedGoogle Scholar
  92. 92.
    Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 1996; 39: 1754–60.PubMedGoogle Scholar
  93. 93.
    Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671–8.Google Scholar
  94. 94.
    Bacon PA, Moots RJ, Exley AR, et al. VITAL assessment of vasculitis. Clin Exp Rheumatol 1995; 13: 275–8.PubMedGoogle Scholar
  95. 95.
    Ikehara S. Intractable diseases and bone marrow transplantation. Pathology Int 1994; 44: 817–26.Google Scholar
  96. 96.
    Marmont AM, Van Bekkum DW. Perspective: stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered question. Bone Marrow Transplant 1995; 16: 497–8.PubMedGoogle Scholar
  97. 97.
    Baldwin JL, Storb R, Thomas ED, et al. Bone marrow transplantation in patients with gold-induced aplasia. Arthritis Rheum 1977; 20: 1043–8.PubMedGoogle Scholar
  98. 98.
    Jacobs P, Vincent MD, Martell RW. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia. Bone Marrow Transplant 1986; 1: 237–9.PubMedGoogle Scholar
  99. 99.
    Lowenthal RM, Cohen ML, Atkinson K, et al. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993; 20: 137–40.PubMedGoogle Scholar
  100. 100.
    Van Bekkum DW, Kinwel-Bohre EP, Houben PF, et al. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA 1989; 86: 1090–4.Google Scholar
  101. 101.
    Knaan-Shanzer S, Houben P, Kinwel-Bohre EP, et al. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant 1992; 8: 333–8.Google Scholar
  102. 102.
    Van Bekkum DW. BMT in experimental autoimmune diseases. Bone Marrow Transplant 1993; 11: 183–7.PubMedGoogle Scholar
  103. 103.
    Karussi DM, Slavin S, Lehmann D, et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol 1992; 148: 1693–8.Google Scholar
  104. 104.
    Van Gelder M, Kinwel-Bohre EP, Van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic bone marrow transplantation. Bone Marrow Transplant 1993; 11: 233–41.PubMedGoogle Scholar
  105. 105.
    Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 1994; 12: 125–35.PubMedGoogle Scholar
  106. 106.
    Slavin S. Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rational for ABMT. Bone Marrow Transplant 1993; 12: 85–8.PubMedGoogle Scholar
  107. 107.
    Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Int Med 1981; 141: 758–63.Google Scholar
  108. 108.
    Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation. Cancer 1986; 57: 2061–9.PubMedGoogle Scholar
  109. 109.
    Goldberg MA, Antin JH, Guinon EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114–8.PubMedGoogle Scholar
  110. 110.
    Gardner SF, Lazarus HM, Bednarczyk EM, et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 1993; 12: 139–44.PubMedGoogle Scholar
  111. 111.
    Marmont AM. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol 1997; 24 Suppl. 48: 13–8.Google Scholar
  112. 112.
    Tyndall A. Haematopoietic stem cell transplantation in rheumatic diseases other then systemic sclerosis and systemic lupus erythematosus. J Rheumatol 1997; 24 Suppl. 48: 94–7.Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Ruth Richmond
    • 1
  • Tracy W. McMillan
    • 2
  • Raashid A. Luqmani
    • 1
  1. 1.Department of RheumatologyUniversity of Edinburgh, Western General HospitalEdinburghScotland
  2. 2.Pharmacy DepartmentWestern General HospitalEdinburghScotland

Personalised recommendations